CompletedPhase 1NCT04103489
The Use of Eculizumab in HELLP Syndrome
Studying HELLP syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Arthur J Vaught, MDJohns Hopkins University
- Intervention
- Eculizumab(drug)
- Enrollment
- 3 target
- Eligibility
- 18-50 years · FEMALE
- Timeline
- 2021 – 2023
Study locations (1)
- The Johns Hopkins University, Baltimore, Maryland, United States
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04103489 on ClinicalTrials.govOther trials for HELLP syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07151339Pilot Project Renal and Cardiovascular Tertiary Prevention in PreeclampsiaUniversity Hospital Schleswig-Holstein
- RECRUITINGNCT05500989PlacEntal Acute Atherosis RefLecting Subclinical AtherosclerosisMaastricht University Medical Center
- RECRUITINGNCT06377878The Preeclampsia RegistryPreeclampsia Foundation